search
Back to results

Mobile Microwave-based Diagnosis and Monitoring of Stroke (MODS)

Primary Purpose

Stroke, Acute, Intracerebral Hemorrhage

Status
Recruiting
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Hemorrhagic stroke group (group A)
Ischemic stroke group (group B)
Stroke mimic group (group C)
Sponsored by
Helse Stavanger HF
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Stroke, Acute

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient with clinical signs of stroke
  • Patient should be ≥ 18 years of age
  • Patient/next of kin confirms orally that the patient wants to participate in the trial (during acute phase)
  • Signed Informed Consent Form (after acute phase)

Exclusion Criteria:

  • Pregnant or nursing woman
  • Fertile woman where pregnancy cannot be excluded
  • Patient diagnosed with a condition associated with risk of poor protocol compliance
  • The diagnostic procedure is deemed to interfere with the standard of care
  • Any other condition or symptoms preventing the patient from entering the study, according to the investigator´s judgment
  • Any patient that according to the Declaration of Helsinki is deemed unsuitable for study enrolment

Sites / Locations

  • Haukeland University HospitalRecruiting
  • Norlandsykehuset HF
  • Statoil AsRecruiting
  • Stavanger University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Hemorrhagic stroke group (group A)

Ischemic stroke group (group B)

Stroke mimic group (group C)

Arm Description

Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.

Patient group B is defined as patients that are diagnosed with ischemic stroke.

Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.

Outcomes

Primary Outcome Measures

To evaluate the diagnostic ability of the device to diagnose hemorrhagic stroke and ischemic stroke in the prehospital and hospital setting
The diagnostic ability as measured by the area under the curve of the device for patient groups (group C vs. groups A + B) using the LOOCV method

Secondary Outcome Measures

Adverse events within 24 hours
Any adverse events occurring within 24 hours from the measurement procedure(s)
To evaluate the diagnostic ability of the device to differentiate patients with stroke mimics
To evaluate the diagnostic ability of the device to differentiate patients with stroke mimics from patients with stroke (hemorrhagic stroke and ischemic stroke) in the prehospital and hospital setting
To evaluate the delivery of adequate measurement data from the device
To evaluate the delivery of adequate measurement data from the device in the prehospital and hospital setting
To evaluate the amount of time needed to perform the measurement procedures
To evaluate the amount of time needed to perform the measurement procedures in the prehospital and hospital settings

Full Information

First Posted
February 1, 2018
Last Updated
February 4, 2020
Sponsor
Helse Stavanger HF
Collaborators
Haukeland University Hospital, Equinor, Medfield Diagnostics, Nordlandssykehuset HF
search

1. Study Identification

Unique Protocol Identification Number
NCT04257149
Brief Title
Mobile Microwave-based Diagnosis and Monitoring of Stroke
Acronym
MODS
Official Title
Mobile Microwave-based Diagnosis and Monitoring of Stroke: on the Road Towards Improved Stroke Triage and Care, Including Prehospital Initiation of Thrombolytic Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2018 (Actual)
Primary Completion Date
February 2022 (Anticipated)
Study Completion Date
February 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Helse Stavanger HF
Collaborators
Haukeland University Hospital, Equinor, Medfield Diagnostics, Nordlandssykehuset HF

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a prospective, open, multicentre trial that will enrol patients with clinical signs of stroke in the acute phase admitted for CT scan. The study assesses the diagnostic capability and safety of Strokefinder MD100.
Detailed Description
This is a prospective, open, multicentre trial that will enrol patients with clinical signs of stroke in the acute phase admitted for CT scan. The investigator will assess and control the inclusion/exclusion criteria. If the patient is confirmed to be suitable for the trial, the patient is asked to give oral informed consent. If the answer is affirmative the microwave measurement will be performed. The procedure will take less than five minutes (the duration of the actual measurement procedure is 1.5 minutes) and will not interfere with the patient's standard of care during the hospital stay. Written informed consent is acquired by the investigator, as soon as possible after the acute phase of care is completed. The measurement data will be evaluated for the presence of signal artifacts. The diagnostic ability of the device will be evaluated using a leave-one-out cross validation (LOOCV) method with the CT diagnosis as ground truth. Safety will be evaluated throughout the trial, and a safety follow-up will be performed by the investigator 24 hours after the last microwave measurement. No further follow-up of patients is planned.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke, Acute, Intracerebral Hemorrhage

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Hemorrhagic stroke group (group A)
Arm Type
Experimental
Arm Description
Patient group A is defined as patients that are diagnosed with hemorrhagic stroke.
Arm Title
Ischemic stroke group (group B)
Arm Type
Experimental
Arm Description
Patient group B is defined as patients that are diagnosed with ischemic stroke.
Arm Title
Stroke mimic group (group C)
Arm Type
Experimental
Arm Description
Patient group C is defined as patients with stroke mimics, i.e. with initially suspected stroke but not diagnosed with stroke.
Intervention Type
Diagnostic Test
Intervention Name(s)
Hemorrhagic stroke group (group A)
Intervention Description
Group A: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
Intervention Type
Diagnostic Test
Intervention Name(s)
Ischemic stroke group (group B)
Intervention Description
Group B: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
Intervention Type
Diagnostic Test
Intervention Name(s)
Stroke mimic group (group C)
Intervention Description
Group C: A microwave measurement (Stroke finder MD100) will be performed with the patient lying on the ambulance stretcher, in the hospital bed or another suitable surface.
Primary Outcome Measure Information:
Title
To evaluate the diagnostic ability of the device to diagnose hemorrhagic stroke and ischemic stroke in the prehospital and hospital setting
Description
The diagnostic ability as measured by the area under the curve of the device for patient groups (group C vs. groups A + B) using the LOOCV method
Time Frame
Baseline
Secondary Outcome Measure Information:
Title
Adverse events within 24 hours
Description
Any adverse events occurring within 24 hours from the measurement procedure(s)
Time Frame
Baseline to 24 hours
Title
To evaluate the diagnostic ability of the device to differentiate patients with stroke mimics
Description
To evaluate the diagnostic ability of the device to differentiate patients with stroke mimics from patients with stroke (hemorrhagic stroke and ischemic stroke) in the prehospital and hospital setting
Time Frame
Baseline
Title
To evaluate the delivery of adequate measurement data from the device
Description
To evaluate the delivery of adequate measurement data from the device in the prehospital and hospital setting
Time Frame
Baseline
Title
To evaluate the amount of time needed to perform the measurement procedures
Description
To evaluate the amount of time needed to perform the measurement procedures in the prehospital and hospital settings
Time Frame
Basline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient with clinical signs of stroke Patient should be ≥ 18 years of age Patient/next of kin confirms orally that the patient wants to participate in the trial (during acute phase) Signed Informed Consent Form (after acute phase) Exclusion Criteria: Pregnant or nursing woman Fertile woman where pregnancy cannot be excluded Patient diagnosed with a condition associated with risk of poor protocol compliance The diagnostic procedure is deemed to interfere with the standard of care Any other condition or symptoms preventing the patient from entering the study, according to the investigator´s judgment Any patient that according to the Declaration of Helsinki is deemed unsuitable for study enrolment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Martin Kurz, PhD
Phone
47246847
Email
martin.kurz@sus.no
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martin Kurz, PhD
Organizational Affiliation
Helse Stavanger HF
Official's Role
Principal Investigator
Facility Information:
Facility Name
Haukeland University Hospital
City
Bergen
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lars Thomassen, PhD
Phone
55975000
Email
lars.thomassen@helse-bergen.no
Facility Name
Norlandsykehuset HF
City
Bodø
Country
Norway
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Carlsson
Phone
75534000
Email
Maria.Carlsson@nordlandsykehuset.no
Facility Name
Statoil As
City
Stavanger
ZIP/Postal Code
4017
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Atle Houg Ringheim
Phone
95854340
Email
atring@statoil.com
Facility Name
Stavanger University Hospital
City
Stavanger
ZIP/Postal Code
4017
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Martin Kurz
Phone
47246847
Email
martin.kurz@sus.no

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Mobile Microwave-based Diagnosis and Monitoring of Stroke

We'll reach out to this number within 24 hrs